Institute of Biophysics and Cell Engineering offers monocytic dendritic cell-based cancer treatment services to consumers, including adult cancer treatment services In accordance with the medical license a medical license under an outsourcing agreement, and is looking for partners interested in a distribution services agreement.

Methods of immunotherapy of oncological diseases using a biomedical cell product (BMCP) based on the patient's monocytic dendritic cells (DC) are based on the ability of DC to stimulate a targeted immune response to a specific tumor and achieve a clinical effect. The treatment uses the registered BMCP "Dendritic monocytic cells" (TU BY 100217351.016-2022).

Developers: State Scientific Institution "Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus", State Institution "Republican Scientific and Practical Center for Epidemiology and Microbiology", Educational Institution "Belarusian State Medical University".

Improved treatment results for oncological diseases: pancreatic cancer (C25 according to ICD-10), bladder cancer (C23 according to ICD-10).

Scope - Medicine, oncology.

Consumers of the products are healthcare organizations providing medical care to patients in outpatient, inpatient, and day hospital settings.

More information about paid services for the population can be found on the Institute's website here.

Information is posted in Album of promising developments of the NAS of Belarus organizations for the real sector of the economy (2023), , стр. 290-291. (in Russian)

The proposed methods of cellular immunotherapy of oncological diseases are competitive due to the fact that traditional chemotherapy and radiation therapy are not always effective.

Medical services associated with cellular therapy are provided to patients of the Republic of Belarus and foreign citizens.

Methods of cellular immunotherapy of oncological diseases using DC-based BMCP allow to increase the relapse-free period and regulate the timing of subsequent lines of chemotherapy. Monitoring of clinical and clinical laboratory parameters of the patients' condition did not reveal any side effects of therapy, the use of DC-based BMCP was safe and well tolerated. High immunological effectiveness of the treatment was shown, which was manifested in an increase in the content of tumor-specific T-cells and a decrease in circulating tumor cells and T-regulatory cells after treatment with DC.

The results of a clinical study have shown that the use of DC in pancreatic cancer (PC) stabilizes the tumor process in 40-50% of cases, sometimes with its partial or complete regression (5-15%), and reduces the risk of metastasis. It has been established that additional DC cell therapy (at least 3 courses) against the background of standard drug treatment for bladder cancer (BC) in the adjuvant regimen can significantly increase one-year relapse-free survival after radical treatment in 81.3% of patients. The maximum clinical effect can be expected with a course of dendritic cell-based BMCP in the adjuvant regimen after removal of the primary tumor in order to prevent relapse and destroy micrometastases.

The developed treatment method has shown good tolerability and safety for the patient, side effects are rare. The method is environmentally safe.

The Department of Cell Therapy of the State Scientific Institution “Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus” provides medical services to the population on a paid basis.

1. Instructions for use "Method of treating patients with pancreatic cancer using monocytic dendritic cells", reg. No. 093-0619 dated 09/06/2019.(in Russian)
2. Instructions for use "Method of treating patients with recurrent non-muscle-invasive bladder cancer using autologous dendritic cell-based BMCP", reg. No. 190-1220 dated 01/28/2021.(in Russian)

State Scientific Institution "Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus" is a leading scientific center in the field of biophysics.

Directions of fundamental and applied scientific research of the Institute.

In the field of medical biotechnology:
- genetic engineering - development of innovative biomedical cell products based on genetically modified cells;
- immunology and allergology - development of new methods of treatment and diagnosis of allergic diseases and immune dysfunctions;
- innovative vaccines - development of prototypes of domestic DNA and RNA vaccines for the prevention of viral diseases;
- new approaches to diagnostics - development of new technologies for early diagnosis of diseases and methods of personalized medicine aimed at improving the quality of human life;
- genome editing - somatic, induced pluripotent stem cells, which will allow treating diseases, including orphan, genetic;
- synthetic morphogenesis - including tissue and organ engineering.

In the field of bioinformatics technologies:
- structure-based design of new-generation drugs, development of innovative targeted antitumor and antiviral drugs using structural bioinformatics methods;
- synthesis of targeted drugs and their testing in vitro.

In the field of nanotheranostics and personalized nanomedicine:
- development of means of targeted delivery of new-generation therapeutic drugs using nanomaterials;
- development of biological nanochips for disease diagnostics;
- study of broad-spectrum biocompatible nanomaterials for the creation of biomedical cellular products, artificial organs, fundamentally new materials with antimicrobial, antiviral and anti-inflammatory activity.

Activities of the Center for Experimental and Applied Virology:
- culturing viruses, developing new methods for culturing human viruses to create diagnostic tools, medical prevention and treatment of viral diseases;
- creation of vaccine prototypes - against influenza (inactivated and recombinant), against African swine fever (vector), against pulmonary tuberculosis (therapeutic based on donor dendritic cells), innovative drugs against influenza.

Over the past years, the Institute has implemented a number of international contracts and agreements within the Framework Programs of the European Union, as well as with leading scientific centers, foundations, and societies.

Consumers interested in purchasing services for the treatment of patients with cancer using monocytic dendritic cells, including services using these methods for adult patients In accordance with the medical license under an outsourcing agreement.

Partners interested in purchasing services for the treatment of patients with cancer using monocytic dendritic cells, including services using these methods for adult patients In accordance with the medical license under a distribution services agreement.